Recent advances in the generation of cardiomyocytes (CMs) from human pluripotent stem
cells (hPSCs), in conjunction with the promising outcomes from preclinical and clinical …

To meet the need of a large quantity of hPSC-derived cardiomyocytes (CM) for pre-clinical
and clinical studies, a robust and scalable differentiation system for CM production is …

Human pluripotent stem cell (hPSC)-derived cardiomyocytes have attracted attention as an
unlimited source of cells for cardiac therapies. One of the factors to surmount to achieve this …

Cardiomyocytes (CMs) generated from human pluripotent stem cells (hPSCs) are a potential
cell source for regenerative therapies, drug discovery and disease modeling. All these …

The human heart is considered a non-regenerative organ. Worldwide, cardiovascular
diseases continue to be the leading cause of death. Despite advances in cardiac treatment …

A promising cell-therapy approach for heart failure aims at differentiating human pluripotent
stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease …

Regenerative medicine, including preclinical studies in large animal models and tissue
engineering approaches as well as innovative assays for drug discovery, will require the …

Cardiac regenerative therapy with human pluripotent stem cells (hPSCs), such as human
embryonic stem cells and induced pluripotent stem cells, has been hampered by the lack of …

Cardiomyocytes derived from human pluripotent stem cells (hPSCs) are emerging as an
invaluable alternative to primarily sourced cardiomyocytes. The potentially unlimited number …

Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a
most promising option for cell-based cardiac repair. Hence, various protocols have been …